论文部分内容阅读
目的:探讨非小细胞肺癌(NSCLC)患者胸膜转移瘤中NOK表达及其与患者生存期的相关性。方法:选取我科2014年至2015年收治的Ⅳ期NSCLC患者67例,用软式胸腔镜取胸膜转移瘤和瘤旁胸膜,采用免疫组化法测定NOK的表达情况,分析胸膜转移瘤和瘤旁胸膜中NOK的表达的无差异性;对患者进行随访,并分析胸膜转移瘤和瘤旁胸膜中NOK的表达与患者生存期的相关性。结果:1Ⅳ期NSCLC患者胸膜转移瘤中NOK的表达明显高于瘤旁胸膜,具有统计学差异(P<0.05);2Ⅳ期NSCLC患者胸膜转移瘤中NOK的表达量与患者的生存期呈负相关,瘤旁胸膜中NOK的表达量与患者的生存期无显著相关性。结论:NSCLC患者胸膜转移瘤中NOK的表达异常上调,且与患者的生存期呈负相关,可做为判断Ⅳ期NSCLC患者生存期的参考指标。
Objective: To investigate the expression of NOK in pleural metastases of patients with non-small cell lung cancer (NSCLC) and its relationship with the survival of patients. Methods: A total of 67 NSCLC patients with stage Ⅳ NSCLC admitted from 2014 to 2015 in our department were enrolled in this study. Pleural metastases and para-pleural pleura were obtained by soft thoracoscopy. The expression of NOK was detected by immunohistochemistry. There was no difference in the expression of NOK between adjacent pleura; the patients were followed up, and the correlation between the expression of NOK in pleural metastases and para-pleural pleura was analyzed with the survival of patients. Results: The expression of NOK in pleural metastases of stage Ⅳ NSCLC patients was significantly higher than that of adjacent pleural tumors (P <0.05). The expression of NOK in pleural metastases was negatively correlated with the survival of patients in stage ⅡⅣ NSCLC There was no significant correlation between the expression of NOK in pleural effusion and the survival of patients. CONCLUSIONS: The abnormal expression of NOK in pleural metastases of patients with NSCLC was abnormally increased, and negatively correlated with the survival of patients with NSCLC. It may be used as a reference index to determine the survival of patients with stage Ⅳ NSCLC.